References

Elite Swing Mechanics

Improve your Baseball Swing

Get Instant Access

1. Jervell A, Lange-Neilsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J 1957;54:59-68.

2. Romano C, Gemme G, Pongiglione R. Artimie cardiac rare dell'eta pediatrica. Clin Pediatr 1963,45:656-683.

3. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc 1964;54:103-106.

4. Moss AJ. Management of patients with the hereditary long QT syndrome. J Cardiovasc Electrophysiol 1998;9(6):668-674.

5. Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998;338(24):1709-1714.

6. Schwartz PJ, Priori SG, Dumaine R, et al. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med 2000;343(4):262-267.

7. Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 1998;49:263-274.

8. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, et al. Mapping of a gene for long QT syndrome to chromosome 4q25-4q27. Am J Hum Genet 1995;57(5):1114-1122.

9. Schwartz PJ, Priori SG. The long QT syndrome. ANE 1998;3(1):63-73.

10. Dumaine R, Wang Q, Keating MT, Hartmann HA, Schwartz PJ, Brown AM, et al. Multiple mechanisms of Na+ channel-linked long-QT syndrome. Circ Res 1996;78(5):916-924.

11. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384(6604):80-83.

12. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 1995;81(2):299-307.

13. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 1997;17(3):267-268.

14. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97(2):175-187.

15. Tyson J, Tranebjaerg L, Bellman S, Wren C, Taylor JF, Bathen J, et al. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum Mol Genet 1997;6(12):2179-2185.

16. Demolombe S, Baro I, Pereon V, Bliek J, Mohammad-Panah R, Pollard H, et al. A dominant negative isoform of the long QT syndrome 1 gene product. J Biol Chem 1998;273(12):6837-6843.

17. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, et al Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 1995;4(9):1603-1607.

18. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995;92(10):2929-2934.

19. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin JA, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995;92(12):3381-3386.

20. Wilde AA, Jongbloed RJ, Doevendans PA, Duren DR, Hauer RN, van Langen IM, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999;33(2):327-332.

21. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88(2):782-784.

22. Lehmann MH, Suzuki F, Fromm BS, Frankovich D, Elko P, Steinman RT, et al. T wave "humps" as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol 1994;24(3):746-754.

23. Malfatto G, Beria G, Sala S, Bonazzi O, Schwartz PJ. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol 1994;23(2):296-301.

24. Zareba W, Moss AJ, le Cessie S, Hall WJ. T wave alternans in idopathic long QT syndrome. J Am Coll Cardiol 1994;23(7):1541-1546.

25. Linker NJ, Colonna P, Kekwick CA, Till J, Camm AJ, Ward DE. Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol 1992;69(6):634-638.

26. Priori SG, Mortara DW, Napolitano C, Diehl L, Paganini V, Cantu F, et al. Evaluation of the spatial aspects of T-wave complexity in the long-QT syndrome. Circulation 1997;96(9):3006-3012.

27. De Ferrari GM, Nador F, Beria G, Sala S, Lotto A, Schwartz PJ. Effect of calcium channel block on the wall motion abnormality of the idiopathic long QT syndrome. Circulation 1994;89(5):2126-2132.

28. Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999;99(4):518-528.

29. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327(12):846-852.

30. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99(4):529-533.

31. El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. Circulation 1997;96(12):4392-4399.

32. Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res 1993;72(3):631-650.

33. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84(3):1136-1144.

34. Zareba W, Moss AJ, le Cessie S, Locati EH, Robinson JL, Hall WJ, et al. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol 1995;26(7):1685-1691.

35. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94(6):1471-1474.

36. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998;339(14):960-965.

37. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM. Electrophysiologic testing in patients with the long QT syndrome. Circulation 1985;71(1):63-71.

38. Moss AJ, Zareba W, Hall WJ, Robinson JL, Benhorin J, Locati-Heilbrun E, et al. Effectiveness and limitations of ß-blocker therapy in long QT syndrome. Circulation 2000;101(6):616-623.

39. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994;89(4):1681-1689.

40. Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998;97(5):451-456.

41. Moss AJ, Liu JE, Gottlieb S, Locati EH, Schwartz PJ, Robinson JL. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation 1991;84(4):1524-1529.

42. Eldar M, Griffin JC, Van Hare GF, Witherell C, Bhandari A, Benditt D, et al. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 1992;20(4):830-837.

43. Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation 1991;84(2):503-511.

44. De Ferrari GM, Locati EH, Priori SG, Schwartz PJ. Left cardiac sympathetic denervation in long QT syndrome patients. J Interv Cardiol 1995;8(6 Suppl):776-781.

45. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996;94(5):1018-1022.

46. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996;94(4):817-823.

47. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96(9):2778-2781.

48. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21(5):1029-1034.

49. Chung MK, Schweikert RA, Wilkoff BL, Niebauer MJ, Pinski SL, Trohman RG, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998;32(1):169-176.

50. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13(7):1002-1003.

51. van Haarst AD, van't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998;64(5):542-546.

52. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromy-cin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996;28(7):1836-1848.

53. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med 1989;111(7):549-551.

54. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280(20):1774-1776.

55. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270(21):2590-2597.

56. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,1-sotalol. Circulation 1996;94(10):2535-2541.

57. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996;131(6):1184-1191.

58. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998;37(2):324-334.

59. Kaab S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA, et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996;78(2):262-273.

60. Kaab S, Dixon J, Duc J, Ashen D, Nabauer M, Beuckelmann DJ, et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998;98(14):1383-1393.

61. Choy AM, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34(2):396-401.

62. Prystowsky EN. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Am J Cardiol 1996;78(8A):35-41.

63. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93(3):407-411.

64. Daleau P, Turgeon J. Triamterene inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Circ Res 1994;74(6):1114-1120.

65. Fiset C, Drolet B, Hamelin BA, Turgeon J. Block of Iks by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther 1997;283(1):148-156.

66. Houltz B, Darpo B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJ, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998;21(5):1044-1057.

67. Thibault B, Nattel S. Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. J Cardiovasc Electrophysiol 1999;10(3):472-481.

68. Myerburg RJ, Kloosterman M, Yamamura K, Mitrani R, Interian A, Jr, Castellanos A. The case for inpatient initiation of antiarrhythmic therapy. J Cardiovasc Electrophysiol 1999;10(3):482-487.

69. Roden DM. A practical approach to torsade de pointes. Clin Cardiol 1997;20(3):285-290.

70. Assimes TL, Malcolm I. Torsade de pointes with sotalol overdose treated successfully with lidocaine. Can J Cardiol 1998;14(5):753-756.

71. Kurita T. Antiarrhythmic effect of parenteral magnesium on ventricular tachycardia associated with long QT syndrome. Magnes Res 1994;7(2):155-157.

72. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997;96(8):2595-2600.

73. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392(6673):293-296.

74. Alings M, Wilde A. "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999;99(5):666-673.

75. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999;33(1):5-15.

76. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988;62(1):116-126.

77. Di Diego JM, Sun ZQ, Antzelevitch C. I(to) and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol 1996;271(2 Pt 2):H548-61.

78. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27(5):1061-1070.

79. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997;95(9):2277-2285.

80. Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997;8(3):325-331.

81. Lukas A, Antzelevitch C. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. Cardiovasc Res 1996;32(3):593-603.

82. Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998;9(5):508-512.

83. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97(5):457-460.

84. Belhassen B, Shapiral, Shoshani D, Paredes A, Miller H, LaniadoS. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75(4):809-816.

85. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10(10):1301-1312.

86. Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardio-vasc Electrophysiol 1998;9(11):1167-1172.

87. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994;71(3):215-218.

88. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a review. Pacing Clin Electrophysiol 1995;18(6):1298-1314.

89. Thiene G, Basso C, Danieli G, Rampazzo A, Corrado D, Nava A. Arrhythmogenic right ventricular cardiomyopathy. Trends Cardiovasc Med 1997;7:84-90.

90. Furlanello F, Bertoldi A, Dallago M, Furlanello C, Fernando F, Inama G, et al. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol 1998;21(1 Pt 2):331-335.

91. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996;276(3):199-204.

92. Tonet JL, Castro-Miranda R, Iwa T, Poulain F, Frank R, Fontaine GH. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1991;67(13):1153.

93. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982;65(2):384-398.

94. Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation 1998;97(16):1571-1580.

95. Fontaine G, Fontaliran F, Frank R. Arrhythmogenic right ventricular cardiomyopathies: clinical forms and main differential diagnoses. Circulation 1998;97(16):1532-1535.

96. Globits S, Kreiner G, Frank H, Heinz G, Klaar U, Frey B, et al. Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. Circulation 1997;96(8):2633-2640.

97. CorradoD, Basso C, Thiene G, McKenna WJ, DaviesMJ, FontaliranF, etal. Spectrum of clinicopatho-logic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997;30(6):1512-1520.

98. Nava A, Thiene G, Canciani B, Scognamiglio R, Daliento L, Buja G, et al. Familial occurrence of right ventricular dysplasia: a study involving nine families. J Am Coll Cardiol 1988;12(5):1222-1228.

99. Rampazzo A, Nava A, Miorin M, Fonderico P, Pope B, Tiso N, et al. ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. Genomics 1997;45(2):259-263.

100. Ahmad F, Li D, Karibe A, Gonzalez O, Tapscott T, Hill R, et al. Localization of a gene responsible for arrhythmogenic right ventricular dysplasiato chromosome 3p23. Circulation 1998;98(25):2791-2795.

101. Severini GM, Krajinovic M, Pinamonti B, Sinagra G, Fioretti P, Brunazzi MC, et al. A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. Genomics 1996;31(2):193-200.

102. Coonar AS, Protonotarios N, Tsatsopoulou A, Needham EW, Houlston RS, Cliff S, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 1998;97(20):2049-2058.

103. Hermida JS, Minassian A, Jarry G, Delonca J, Rey JL, Quiret JC, et al. Familial incidence of late ventricular potentials and electrocardiographic abnormalities in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1997;79(10):1375-1380.

104. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med 1996;335(16):1190-1196.

105. Foale RA, Nihoyannopoulos P, Ribeiro P, McKenna WJ, Oakley CM, Krikler DM, et al. Right ventricular abnormalities in ventricular tachycardia of right ventricular origin: relation to electrophysiological abnormalities. Br Heart J 1986;56(1):45-54.

106. Blake LM, Scheinman MM, Higgins CB. MR features of arrhythmogenic right ventricular dysplasia. AJR Am J Roentgenol 1994;162(4):809-812.

107. Daubert C, Descaves C, Foulgoc JL, Bourdonnec C, Laurent M, Gouffault J. Critical analysis of cineangiographic criteria for diagnosis of arrhythmogenic right ventricular dysplasia. Am Heart J 1988;115(2):448-459.

108. Daubert C, Mabo P, Druelles P, Foulgoc JL, De Place C, Paillard F. Benefits and limits of selective right ventricular cineangiography in arrhythmogenic right ventricular dysplasia. Eur Heart J 1989;10 Suppl D:46-8.

109. Matsuo K, Nishikimi T, Yutani C, Kurita T, Shimizu W, Taguchi A, et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation 1998;98(22):2433-2440.

110. Turrini P, Angelini A, Thiene G, Buja G, Daliento L, Rizzoli G et al. Late potentials and ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 1999;83(8):1214-1219.

111. Kinoshita O, Fontaine G, Rosas F, Elias J, Iwa T, Tonet J, et al. Time- and frequency-domain analyses of the signal-averaged ECG in patients with arrhythmogenic right ventricular dysplasia. Circulation 1995;91(3):715-721.

112. Tada H, Shimizu W, Ohe T, Hamada S, Kurita T, Aihara N, et al. Usefulness of electron-beam computed tomography in arrhythmogenic right ventricular dysplasia. Relationship to electrophysiological abnormalities and left ventricular involvement. Circulation 1996;94(3):437-444.

113. Peeters HA, SippensGroenewegen A, Schoonderwoerd BA, Wever EF, Grimbergen CA, Hauer RN, et al. Body-surface QRST integral mapping. Arrhythmogenic right ventricular dysplasia versus idiopathic right ventricular tachycardia. Circulation 1997;95(12):2668-2676.

114. De Ambroggi L, Aime E, Ceriotti C, Rovida M, Negroni S. Mapping of ventricular repolarization potentials in patients with arrhythmogenic right ventricular dysplasia: principal component analysis of the ST-T waves. Circulation 1997;96(12):4314-4318.

115. Marcus FI, Fontaine GH, Frank R, Gallagher JJ, Reiter MJ. Long-term follow-up in patients with arrhythmogenic right ventricular disease. Eur Heart J 1989;10 (Suppl D):68-73.

116. Canu G, Atallah G, Claudel JP, Champagnac D, Desseigne D, Chevalier P, et al. [Prognosis and long-term development of arrhythmogenic dysplasia of the right ventricle]. Arch Mal Coeur Vaiss 1993;86(1):41-48.

117. Pinamonti B, Di Lenarda A, Sinagra G, Silvestri F, Bussani R, Camerini F. Long-term evolution of right ventricular dysplasia-cardiomyopathy. The Heart Muscle Disease Study Group. Am Heart J 1995;129(2):412-415.

118. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninduc-ible ventricular tachycardia. Circulation 1992;86(1):29-37.

119. Link MS, Wang PJ, Haugh CI, Homoud MK, Foote CB, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol 1997;1(1):41-48.

120. Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol 1998;32(3):724-728.

121. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93(5):841-842.

122. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiography analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92(4):785-789.

123. Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation 1995;92(4):700-704.

124. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72(12):970-972.

125. Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile ofhypertrophic cardiomyop-athy identified de novo in rural communities. J Am Coll Cardiol 1999;33(6):1590-1595.

126. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26(6):1529-1536.

127. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;92(7):1680-1692.

128. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336(11):775-785.

129. Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999;281(18):1746-1752.

130. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62(5):999-1006.

131. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77(5):701-712.

132. Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997;16(4):379-382.

133. Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996;13(1):63-69.

134. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995;11(4):438-440.

135. MacRae CA, Ghaisas N, Kass S, Donnelly S, Basson CT, Watkins HC, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995;96(3):1216-1220.

136. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48(2):252-257.

137. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J. 1981;46(2):168-172.

138. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90(6):2743-2747.

139. Fananapazir I, McAreavey D. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol 1997;20(2 Pt 2):478-501.

140. Geibel A, Brugada P, Zehender M, Stevenson W, Waldecker B, Wellens HJ. Value of programmed electrical stimulation using a standardized ventricular stimulation protocol in hypertrophic cardiomyopathy. Am J Cardiol 1987;60(8):738-739.

141. Anderson KP, Stinson EB, Derby GC, Oyer PE, Mason JW. Vulnerability of patients with obstructuve hypertrophic cardiomyopathy to ventricular arrhythmia induction in the operating room. Analysis of 17 patients. Am J Cardiol 1983;51(5):811-816.

142. Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. Br Heart J 1980;43(3):245-251.

143. Wellens HJ, Barr FW, Vanagt EJ. Death after ajmaline administration. Am J Cardiol 1980;45(4):905.

144. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96(9):2987-2991.

145. Lazzeroni E, Picano E, Morozzi L, Maurizio AR, Palma G, Ceriati R, et al. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Circulation 1997;96(12):4268-4272.

146. Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82(6):774-778.

147. Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;32(7):1943-1950.

148. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy—a risk factor for sudden death. N Engl J Med 1998;339(17):1201-1209.

149. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO, 3d, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67(2):169-174.

150. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33(6):1596-1601.

151. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342(6):365-373.

152. Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31(5):1081-1085.

153. Zhu DW, Sun H, Hill R, Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electro-physiol 1998,21(1 Pt 2):299-302.

154. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33(1):206-211.

155. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24(4):880-885.

156. Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 1970;32(5):652-659.

157. McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984;54:802-810.

158. Watson DC, Henry WL, Epstein SE, Morrow AG. Effects of operation on left atrial size and the occurrence of atrial fibrillation in patients wiht hypertrophic subaortic stenosis. Circulation 1977;55:178-181.

159. Fananapazir L, Cannon RO 3d, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructuve hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992;85:2149-2161.

160. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructuve hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-2742.

161. Gadler F, Linde C, Daubert C, McKenna W, Meisel E, Aliot E, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy. Eur Heart J 1999;20:1044-1050.

162. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997;29:435-441.

163. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927-2933.

164. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol 1999;83:903-907.

165. Nishimura RA, Symanski JD, Hurrell DG, Trusty JM, Hayes DL, Tajik AJ. Dual-chamber pacing for cardiomyopathies: a 1996 clinical perspective. Mayo Clin Proc 1996;71:1077-1087.

166. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J 1997;18:1249-1256.

167. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol 1999;34:191-196.

168. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31(2):252-258.

169. Dickman GL, Hassan A, Luckstead EF. Ventricular fibrillation following baseball injury. Physician Sportsmed 1978;6:85-86.

170. Green ED, Simson LR, Kellerman HH, Horowitz RN. Cardiac concussion following softball blow to the chest. Ann Emerg Med 1980;9:155-157.

171. Abrunzio TJ. Commotio cordis: the single, most common cause of traumatic death in youth baseball. Am J Dis Child 1991;145:1279-1282.

172. Kaplan JA, Karofsky PS, Volturo GA. Commotio cordis in two amateur ice hockey players despite the use of commercial chest protectors: case reports. J Trauma 1993;34:151-153.

173. Maron BJ, Strasburger JF, Kugler JD, Bell BM, Brodkey FD, Poliac LC. Survival following blunt chest impact induced cardiac arrest during sports activities in young athletes. Am J Cardiol 1997;79:840-841.

174. Maron BJ, Link MS, Wang PJ, Estes NAM. Clinical profile of commotio cordis: an under-appreciated cause of sudden death in the young during sports and other activities. J Cardiovasc Electrophysiol 1999;10:114-120.

175. Link MS, Ginsburg SH, Wang PJ, Kirchhoffer JB, Estes NAM, Parris YM. Commotio cordis: cardiovascular manifestations of a rare survivor. Chest 1998;114:326-328.

176. Maron BJ, Poliac LC, Kaplan JA, Mueller FO. Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities. N Engl J Med 1995;333:337-342.

177. Adler P, Monticone RCJ. Injuries and deaths related to baseball. In: Kyle SB, ed. Youth Baseball Protective Equipment Project Final Report. Washington, DC: United States Consumer Product Safety Commission, 1996;1-43.

178. Viano DC, Artinion CG. Myocardial conducting system dysfunctions from thoracic impact. J Trauma 1978;18:452-459.

179. Liedtke AJ, Gault JH, Demuth WE. Electrographic and hemodynamic changes following nonpenetrat-ing chest trauma in the experimental animal. Am J Physiol 1974;226:377-382.

180. Cooper GJ, Pearce BP, Stainer MC, Maynard RL. The biomechanical response of the thorax to nonpenetrating impact with particular reference to cardiac injuries. J Trauma 1982;22:994-1008.

181. Link MS, Wang PJ, Pandian NG, et al. An experimental model of sudden death due to low energy chest wall impact (commotio cordis). N Engl J Med 1998;338:1805-1811.

182. Link MS, Wang PJ, VanderBrink BA, et al. Selective activation of the K+ATP channel is a mechanism by which sudden death is produced by low-energy chest-wall impact (commotio cordis). Circulation 1999;100:413-418.

183. Kubota I, Yamaki M, Shibata T, Ikeno E, Hosoya Y, Tomoike H. Role of ATP-sensitive K+ channel on ECG ST segment elevation during about of myocardial ischemia. Circulation 1993;88:1845-1851.

Was this article helpful?

0 0
Baseball For Boys

Baseball For Boys

Since World War II, there has been a tremendous change in the makeup and direction of kid baseball, as it is called. Adults, showing an unprecedented interest in the activity, have initiated and developed programs in thousands of towns across the United States programs that providebr wholesome recreation for millions of youngsters and are often a source of pride and joy to the community in which they exist.

Get My Free Ebook


Post a comment